Chicago— Two trials presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO) provide somewhat discouraging findings on checkpoint inhibitors for second-line treatment of mesothelioma.
In the largest checkpoint inhibitor study in mesothelioma to date, a Phase IB study conducted with the programmed death ligand-1 (PD-L1) inhibitor avelumab (Pfizer), the objective response rate (ORR) among the 53 patients in the study, who had unresectable pleural or